| Literature DB >> 28640889 |
Mark D Kieh1, Elim M Cho1, Ian A Myles1,2.
Abstract
Under a traditional paradigm, only those with the expected background knowledge consume academic literature. The lay press, as well as government and non-government agencies, play a complementary role of extracting findings of high interest or importance and translating them for general viewing. The need for accurate reporting and public advising is paramount when attempting to tackle epidemic outbreaks through behavior change. Yet, public trust in media outlets is at a historic low. The Crisis and Emergency Risk Communication (CERC) model for media reporting on public health emergencies was established in 2005 and has subsequently been used to analyze media reporting on outbreaks of influenza and measles as well as smoking habits and medication compliance. However, no media analysis had yet been performed on the 2013-2016 Ebola Virus Disease (EVD) outbreak. This study compared the EVD information relayed by lay press sources with general review articles in the academic literature through a mixed-methods analysis. These findings suggest that comprehensive review articles could not serve as a source to clarify and contextualize the uncertainties around the EVD outbreak, perhaps due to adherence to technical accuracy at the expense of clarity within the context of outbreak conditions. This finding does not imply inferiority of the academic literature, nor does it draw direct causation between confusion in review articles and public misunderstanding. Given the erosion of the barriers siloing academia, combined with the demands of today's fast-paced media environment, contemporary researchers should realize that no study is outside the public forum and to therefore consider shifting the paradigm to take personal responsibility in the process of accurately translating their scientific words into public policy actions to best serve as a source of clarity.Entities:
Mesh:
Year: 2017 PMID: 28640889 PMCID: PMC5480889 DOI: 10.1371/journal.pone.0179356
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
The Crisis and Emergency Risk Communication (CERC) model for topic scoring.
The CERC model was used to generate topic lists for scoring of accuracy, completeness, as well as enumerating unrelated information.
| Code | Topic/Sub-Topic | Definition | Modifier | Example |
|---|---|---|---|---|
| Objective Information about the outbreak | ||||
| Population statistics related to the outbreak | 1.1.1 | Number dead | ||
| 1.1.2 | Number infected | |||
| 1.1.3 | R' number (1.7–2) | |||
| 1.1.4 | Fatality rate (16–92%) | |||
| What happens to those that contract Ebola | ||||
| Symptoms of Disease | Clinical presentation of patients with Ebola disease | 1.2.1 | Fever | |
| 1.2.2 | Headache | |||
| 1.2.3 | Myalgias | |||
| 1.2.4 | Arthralgias | |||
| 1.2.5 | Abominal pain, nausea, vomiting, diarrhea | |||
| 1.2.6 | Sore throat | |||
| 1.2.7 | Oral ulcers | |||
| 1.2.8 | Confusion | |||
| 1.2.9 | Fatigue | |||
| 1.2.10 | Loss of appetite | |||
| 1.2.11 | Macular-Macolupapular rash | |||
| 1.2.12 | Mucosal Hemorrhages | |||
| 1.2.13 | Hiccups | |||
| Objective lab measurements during Ebola disease | 1.3.1 | Leukopenia, lymphopenia, or leukocytosis | ||
| 1.3.2 | Thrombocytopenia | |||
| 1.3.3 | Transaminitis | |||
| 1.3.4 | Hyperamylasemia | |||
| 1.3.5 | Proteinuria | |||
| 1.3.6 | Hypokalemia | |||
| 1.3.7 | Lactic acidosis | |||
| 1.3.8 | PT/PTT prolongation | |||
| 1.3.9 | Decreased fibrinogen | |||
| 1.3.10 | Viral RNA by PCR | |||
| 1.3.11 | Viral Antibodies | |||
| How the public perceives risk of Ebola and risk factors for contracting Ebola | ||||
| Populations with increased actual risk and severity for whom increased perceived risk is warranted | 2.1.1 | Pregnant females (abortion, placenta previa) | ||
| 2.1.2 | Adults over 45 | |||
| 2.1.3 | Health care providers | |||
| 2.1.4 | Breast feeding infants | |||
| Known environmental factors that increase the risk for Ebola | 2.2.1 | Mucosal-to-body fluid contact with infected individual (blood, urine, saliva, feces, emesis, breast milk, semen) | ||
| 2.2.2 | Consumption of bush meat | |||
| 2.2.3 | Funeral attendance | |||
| 2.2.4 | Citizen of nation with poor health care system | |||
| 2.2.5 | Citizen of nation with porous borders | |||
| 2.2.6 | Living in area of high population density | |||
| 2.2.7 | Citizen of nation with low trust in government or health institutions | |||
| 2.2.8 | Deforestation/Vector & reservoir displacement | |||
| 2.2.9 | Sex if virus present in semen | |||
| 2.2.10 | Not airborne in nature | |||
| 2.2.11 | Not infectious until symptomatic | |||
| Time from exposure to manifestation of symptoms within which concern for disease is valid | 8-10d, never more than 21d | |||
| Diseases that could mimic Ebola and thus impact perceived threat and severity due to false positives | Malaria, Typhoid, Traveler's diarrhea, Yellow fever | |||
| Prevention measures taken to control the outbreak of Ebola | ||||
| Therapeutic/pharmaceutical approaches to prevent contraction of Ebola | Ebola Vaccination | |||
| Environmental and behavioral modifications that can prevent contraction of Ebola | 3.2.1 | Contact and droplet precautions | ||
| 3.2.2 | Isolation/Quarantine of suspected cases | |||
| 3.2.3 | Contact tracing, monitoring 21 days | |||
| 3.2.4 | Quick reporting/recognition of cases | |||
| 3.2.5 | Class II biosafety handling of samples | |||
| 3.2.6 | Frequent cleaning | |||
| 3.2.7 | Behavior change communication/Community engagement | |||
| Appropriate personal protective equipment worn by healthcare workers treated known/suspected cases of Ebola to prevent contraction of disease | 3.3.1 | Training donning and doffing | ||
| 3.3.2 | Observed donning and doffing | |||
| 3.3.3 | No exposed skin | |||
| 3.3.4 | Impermeable gown | |||
| 3.3.5 | Surgical mask | |||
| 3.3.6 | Face shield | |||
| 3.3.7 | Two sets of gloves | |||
| 3.3.8 | N95 mask or Powered air purifying respirator (PAPR) | |||
| 3.3.9 | Boots or shoe covers | |||
| 3.3.10 | Waterproof apron/coverall | |||
| Treatment aimed at preventing disease consequences | 3.4.1 | Volume repletion | ||
| 3.4.2 | Acid base balance | |||
| 3.4.3 | Vasopressers | |||
| 3.4.4 | Oxygen | |||
| 3.4.5 | Pain control | |||
| 3.4.6 | Nutrition | |||
| 3.4.7 | Experimental therapies (Zmapp, Brincidofovir, convalescent serum) | |||
| 3.4.8 | Supportive treatments are only option/no specific therapy | |||
| Trust in information supply | ||||
| Nations impacted by Ebola as measured by one or more cases in their population/on their soil | 4.1.1 | Liberia | ||
| 4.1.2 | Sierra Leone | |||
| 4.1.3 | Guinea | |||
| 4.1.4 | Nigeria | |||
| 4.1.5 | Senegal | |||
| 4.1.6 | Mali | |||
| 4.1.7 | United States | |||
| 4.1.8 | United Kingdom | |||
| 4.1.9 | Italy/Germany | |||
| 4.1.10 | Spain | |||
| Referencing groups or individuals that are subject matter experts deserving trust on informing public | 4.2.1 | WHO/UN | ||
| 4.2.2 | CDC | |||
| 4.2.3 | MSF | |||
| 4.2.4 | NIH | |||
| 4.2.5 | Dept of Transportation | |||
| 4.2.6 | Local Ministries of Health/Dept of health | |||
| 4.2.7 | FDA | |||
| 4.2.8 | Dept of Defense/USAMRIID | |||
| 4.2.9 | USAID | |||
| 4.2.10 | EPA/OSHA—PPE | |||
| 4.2.11 | Red Cross | |||
| 4.2.12 | HHS/ASPR/BRADA/USPHS | |||
| Items not in categories above | ||||
| Information about how Ebola leads to morbidity or mortality | Inflammatory storm, sepsis, DIC, liver necrosis | |||
| Information about the virus that causes Ebola disease | Zaire strain, Filoviridae virus, ssRNA | |||
| Non-human animals that can harbor and/or spread Ebola | Bats | |||
| Information that has nothing to do with current outbreak | Historical data on past outbreaks, information regarding nations involved, etc. | |||
| Any claim that is inconsistent with the information above | ||||
| Any declarative claim that is inconsistent with the information above | "The outbreak began March 2014" stated after outbreak shown to have begun in December 2013 | |||
| Any statement that is factually inaccurate but stated as question of hearsay | "Some are asking if Ebola is spread through the air" | |||
| Any statement that could be misinterpreted due to lacking other pieces of key information | Providing only a partial list of PPE supplies Stating EVD airborne spread “can not be excluded” in context of outbreak conditions | |||
| Statements made without appropriate citation | Academic journal citing LA times or opinion | |||
| Medical Legal (hospital) | The legal requirements of the hospital | Did the hospital properly train their staff or was it allowable for them to release the names of infected nurses | ||
| Medical Legal (Individual) | The legal requirements of the individual | What are the rights under observation or quarantine | ||
| Celebrity donations | People providing money | Charities | ||
| Stigma | Treatment of survivors or nations afflicted as a whole | People pulling children from school | ||
| Geopolitics/Response/Geofinancing | How crisis impacts elections or how global decisions on funding are made | WHO payments, polling numbers, etc | ||
| Dem Republic of Congo | A concurrent outbreak occurred in DRC but was of a different and unrelated strain | Discussed but mentioned it was unrelated |
Fig 1Systematic review inclusion process for academic articles focusing on general review.
(A) The primary search for articles written after the Western African outbreak. (B) A similar search for general topic review articles from 2010 up until the Western African outbreak onset.
The resultant scores for comprehensive review articles under Crisis and Emergency Risk Communication (CERC) model.
Scores for presence or absence of covered topics were generated using the CERC model in Table 1. Citations 111–114 pre-date 2013 EVD outbreak. Red indicates the citation covered the topic, blue indicates the topic was not covered, and grey indicates not applicable.
| Citation | 112 | 113 | 114 | 115 | 1 | 9 | 14 | 15 | 18 | 23 | 26 | 31 | 36 | 38 | 45 | 55–58 | 59 | 60 | 61 | 64 | 68 | 69 | 71 | 74 | 78 | 79 | 83 | 85 | 86 | 89 | 92 | 93 | 97 | 99 | 105 | 116 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number dead | ||||||||||||||||||||||||||||||||||||
| Number infected | ||||||||||||||||||||||||||||||||||||
| R' number (1.9–4.1) | ||||||||||||||||||||||||||||||||||||
| Fatality rate (16–92%) | ||||||||||||||||||||||||||||||||||||
| Fever | ||||||||||||||||||||||||||||||||||||
| Headache | ||||||||||||||||||||||||||||||||||||
| Myalgias | ||||||||||||||||||||||||||||||||||||
| Arthralgias | ||||||||||||||||||||||||||||||||||||
| Abdominal pain, nausea, vomiting, diarrhea | ||||||||||||||||||||||||||||||||||||
| Sore throat/Oral ulcers | ||||||||||||||||||||||||||||||||||||
| Hypotenion/Shock, Multi-organ/system failure | ||||||||||||||||||||||||||||||||||||
| Neurologic/Confusion | ||||||||||||||||||||||||||||||||||||
| Fatigue/Malasie | ||||||||||||||||||||||||||||||||||||
| Shortness of breath, chest pain, cough | ||||||||||||||||||||||||||||||||||||
| Macular-Macolupapular rash | ||||||||||||||||||||||||||||||||||||
| Mucosal Hemmorrhages | ||||||||||||||||||||||||||||||||||||
| Hiccups | ||||||||||||||||||||||||||||||||||||
| Leukopenia, lymphopenia, or leukocytosis | ||||||||||||||||||||||||||||||||||||
| Thrombocytopenia | ||||||||||||||||||||||||||||||||||||
| Transaminitis/Hepatitis | ||||||||||||||||||||||||||||||||||||
| Hyperamylasemia/Pancreatitis | ||||||||||||||||||||||||||||||||||||
| Proteinuria/Edema/low albumin | ||||||||||||||||||||||||||||||||||||
| Electrolyte abnormalities/renal dysfunction | ||||||||||||||||||||||||||||||||||||
| Lactic acidosis | ||||||||||||||||||||||||||||||||||||
| PT/PTT prolongation/Coagulopathy | ||||||||||||||||||||||||||||||||||||
| Decreased fibrinogen/DIC | ||||||||||||||||||||||||||||||||||||
| Viral RNA by PCR | ||||||||||||||||||||||||||||||||||||
| Viral Antibodies | ||||||||||||||||||||||||||||||||||||
| Pregnant females (abortion, placenta previa) | ||||||||||||||||||||||||||||||||||||
| Adults over 45 | ||||||||||||||||||||||||||||||||||||
| Health workers | ||||||||||||||||||||||||||||||||||||
| Breastfeeding infants | ||||||||||||||||||||||||||||||||||||
| Mucosal-to-body fluid contact | ||||||||||||||||||||||||||||||||||||
| Consumption of bush meat (rat, primate) | ||||||||||||||||||||||||||||||||||||
| Unsafe burial practices | ||||||||||||||||||||||||||||||||||||
| Citizen of nation with poor health care system | ||||||||||||||||||||||||||||||||||||
| Citizen of nation with porous borders | ||||||||||||||||||||||||||||||||||||
| Living in area of high population density | ||||||||||||||||||||||||||||||||||||
| Low trust in government or institutions | ||||||||||||||||||||||||||||||||||||
| Deforestation/Vector & resivour displacement | ||||||||||||||||||||||||||||||||||||
| Sex if virus present in semen | ||||||||||||||||||||||||||||||||||||
| Not airborne in nature | ||||||||||||||||||||||||||||||||||||
| Not infectious until symptomatic | ||||||||||||||||||||||||||||||||||||
| Contact and droplet precaustions | ||||||||||||||||||||||||||||||||||||
| Isolation/Quarantine of suspected cases | ||||||||||||||||||||||||||||||||||||
| Contact tracing, monitoring | ||||||||||||||||||||||||||||||||||||
| Quick reporting/recognition of cases | ||||||||||||||||||||||||||||||||||||
| Class II/BSL4 biosafety handling of samples | ||||||||||||||||||||||||||||||||||||
| Environmental decontamination | ||||||||||||||||||||||||||||||||||||
| Behavior change comm/Community engagement | ||||||||||||||||||||||||||||||||||||
| Training donning and doffing | ||||||||||||||||||||||||||||||||||||
| Observed donning and doffing | ||||||||||||||||||||||||||||||||||||
| No exposed skin | ||||||||||||||||||||||||||||||||||||
| Impermiable gown | ||||||||||||||||||||||||||||||||||||
| Surgical mask | ||||||||||||||||||||||||||||||||||||
| Face shield | ||||||||||||||||||||||||||||||||||||
| Two sets of gloves | ||||||||||||||||||||||||||||||||||||
| N95 mask or PAPR | ||||||||||||||||||||||||||||||||||||
| Boots or shoe covers | ||||||||||||||||||||||||||||||||||||
| Waterproof apron/coverall | ||||||||||||||||||||||||||||||||||||
| Volume repletion | ||||||||||||||||||||||||||||||||||||
| Acid base balance | ||||||||||||||||||||||||||||||||||||
| Vasopressers | ||||||||||||||||||||||||||||||||||||
| Oxygen | ||||||||||||||||||||||||||||||||||||
| Pain control | ||||||||||||||||||||||||||||||||||||
| Nutrition | ||||||||||||||||||||||||||||||||||||
| Experimental therapies | ||||||||||||||||||||||||||||||||||||
| Supportive treatment only | ||||||||||||||||||||||||||||||||||||
| Travel bans (not helpful) | ||||||||||||||||||||||||||||||||||||
| Screening Travelers | ||||||||||||||||||||||||||||||||||||
| Liberia | ||||||||||||||||||||||||||||||||||||
| Sierra Leone | ||||||||||||||||||||||||||||||||||||
| Guinea | ||||||||||||||||||||||||||||||||||||
| Nigeria | ||||||||||||||||||||||||||||||||||||
| Senegal | ||||||||||||||||||||||||||||||||||||
| Mali | ||||||||||||||||||||||||||||||||||||
| United States | ||||||||||||||||||||||||||||||||||||
| United Kingdom | ||||||||||||||||||||||||||||||||||||
| Italy/Germany | ||||||||||||||||||||||||||||||||||||
| Spain | ||||||||||||||||||||||||||||||||||||
| WHO/UN | ||||||||||||||||||||||||||||||||||||
| CDC | ||||||||||||||||||||||||||||||||||||
| MSF | ||||||||||||||||||||||||||||||||||||
| NIH | ||||||||||||||||||||||||||||||||||||
| Dept of Transportation | ||||||||||||||||||||||||||||||||||||
| Local Ministries of Health/Dept of Health | ||||||||||||||||||||||||||||||||||||
| FDA | ||||||||||||||||||||||||||||||||||||
| Dept of Defense/USAMRIID | ||||||||||||||||||||||||||||||||||||
| USAID | ||||||||||||||||||||||||||||||||||||
| EPA/OSHA | ||||||||||||||||||||||||||||||||||||
| Red Cross | ||||||||||||||||||||||||||||||||||||
| HHS/ASPR/BRADA/USPHS | ||||||||||||||||||||||||||||||||||||
| Historical Perspective | ||||||||||||||||||||||||||||||||||||
Completeness and accuracy scores by media type.
Aggregate scores for coverage of topics were collected for each media type based on individual media outlets (S1 Table). Nations impacted in the 2013–2016 outbreak were not counted against those sources that pre-dated the outbreak.
| Journals | Wikipedia | Magazines | Newspapers | Blogs | Alternative Sites | |||
|---|---|---|---|---|---|---|---|---|
| Topic/Sub-Topic | Pre-Outbreak | Post-Outbreak | Pre-Outbreak | Post-Outbreak | ||||
| | ||||||||
| Number dead | 100 | 84.4 | 100 | 100 | 28.9 | 36.0 | 71.4 | 19.2 |
| Number infected | 100 | 81.3 | 100 | 100 | 36.8 | 20.7 | 43.6 | 7.7 |
| R' number (1.9–4.1) | 0 | 21.9 | 0 | 0 | 0.0 | 0.3 | 0.0 | 0 |
| Fatality rate (16–92%) | 100 | 71.9 | 100 | 100 | 15.8 | 7.0 | 12.0 | 3.8 |
| | ||||||||
| Fever | 100 | 90.6 | 100 | 100 | 31.6 | 22.3 | 15.0 | 7.7 |
| Headache | 75 | 75.0 | 100 | 100 | 13.2 | 2.3 | 3.0 | 3.8 |
| Myalgia | 100 | 62.5 | 100 | 100 | 10.5 | 2.7 | 2.3 | 3.8 |
| Arthralgia | 25 | 18.8 | 0 | 100 | 7.9 | 1.0 | 1.5 | 0 |
| Abdominal pain, n/v, diarrhea | 100 | 90.6 | 100 | 100 | 23.7 | 12.3 | 9.8 | 0 |
| Sore throat/Oral ulcers | 25 | 28.1 | 0 | 100 | 7.9 | 0.7 | 2.3 | 3.8 |
| Hypotension/Shock, Multi-organ/system failure | 75 | 65.6 | 100 | 100 | 5.3 | 1.0 | 2.3 | |
| Neurologic/Confusion | 100 | 31.3 | 100 | 100 | 2.6 | 0.3 | 0.8 | 0 |
| Fatigue/Malaise | 75 | 71.9 | 100 | 100 | 18.4 | 2.0 | 5.3 | 0 |
| Shortness of breath, chest pain, cough | 100 | 56.3 | 100 | 100 | 0.0 | 1.3 | 0.8 | |
| Macular-Macolupapular rash | 75 | 53.1 | 100 | 100 | 0.0 | 0.3 | 1.5 | 0 |
| Mucosal Hemorrhages | 100 | 90.6 | 100 | 100 | 10.5 | 6.3 | 6.0 | 7.7 |
| Hiccups | 0 | 28.1 | 100 | 0 | 2.6 | 0.0 | 0.0 | 0 |
| | ||||||||
| Leukopenia, lymphopenia, or leukocytosis | 50 | 46.9 | 0 | 100 | 0.0 | 0.0 | 0.0 | |
| Thrombocytopenia | 50 | 43.8 | 0 | 100 | 0.0 | 0.3 | 0.0 | 0 |
| Transaminitis/Hepatitis | 50 | 53.1 | 0 | 100 | 0.0 | 0.3 | 1.5 | 0 |
| Hyperamylasemia/Pancreatitis | 0 | 21.9 | 0 | 0 | 0.0 | 0.0 | 0.0 | 0 |
| Proteinuria/Edema/low albumin | 50 | 31.3 | 0 | 100 | 0.0 | 0.0 | 0.0 | 0 |
| Electrolyte abnormalities/renal dysfunction | 0 | 59.4 | 0 | 100 | 5.3 | 1.7 | 3.8 | |
| Lactic acidosis | 0 | 15.6 | 0 | 0 | 0.0 | 0.0 | 0.0 | 0 |
| PT/PTT prolongation/Coagulopathy | 75 | 37.5 | 100 | 100 | 2.6 | 0.0 | 0.8 | |
| Decreased fibrinogen/DIC | 75 | 62.5 | 100 | 100 | 0.0 | 0.0 | 0.0 | 0 |
| Viral RNA by PCR | 75 | 71.9 | 0 | 100 | 0.0 | 0.7 | 2.3 | 7.7 |
| Viral Antibodies | 75 | 75.0 | 100 | 100 | 0.0 | 0.3 | 0.8 | 0 |
| | ||||||||
| Pregnant females (abortion, placenta previa) | 0 | 15.6 | 0 | 100 | 2.6 | 0.3 | 0.0 | |
| Adults over 45 | 0 | 6.3 | 0 | 0 | 0.0 | 0.0 | 0.8 | 0 |
| Health workers | 75 | 62.5 | 0 | 100 | 42.1 | 14.3 | 19.5 | 3.8 |
| Breastfeeding infants | 0 | 12.5 | 0 | 100 | 2.6 | 0.3 | 1.5 | 0 |
| | ||||||||
| Mucosal-to-body fluid contact | 50 | 87.5 | 100 | 100 | 26.3 | 15.3 | 24.1 | 7.7 |
| Consumption of bush meat (rat, primate) | 50 | 59.4 | 100 | 100 | 7.9 | 2.0 | 3.0 | |
| Unsafe burial practices | 50 | 68.8 | 100 | 100 | 7.9 | 4.7 | 11.3 | 3.8 |
| Citizen of nation with poor health care system | 50 | 56.3 | 100 | 100 | 28.9 | 12.7 | 12.8 | |
| Citizen of nation with porous borders | 0 | 25.0 | 0 | 0 | 5.3 | 1.7 | 3.0 | |
| Living in area of high population density | 0 | 34.4 | 0 | 0 | 5.3 | 1.3 | 0.8 | |
| Low trust in government or institutions | 50 | 34.4 | 0 | 100 | 15.8 | 3.0 | 7.5 | |
| Deforestation/Vector & reservoir displacement | 25 | 6.3 | 0 | 0 | 2.6 | 0.3 | 0.0 | |
| Sex if virus present in semen | 75 | 21.9 | 100 | 100 | 2.6 | 2.0 | 10.5 | 0 |
| Not airborne in nature | 50 | 65.6 | 100 | 100 | 18.4 | 4.0 | 4.5 | 0 |
| Not infectious until symptomatic | 0 | 28.1 | 0 | 100 | 31.6 | 7.7 | 9.0 | 3.8 |
| | 75 | 81.3 | 100 | 100 | 21.1 | 20.0 | 21.1 | 23.1 |
| | 50 | 43.8 | 100 | 100 | 13.2 | 1.3 | 3.0 | 3.8 |
| | 75 | 68.8 | 100 | 100 | 15.8 | 8.3 | 19.5 | 23.1 |
| | ||||||||
| Contact and droplet precautions | 0 | 15.6 | 0 | 0 | 0.0 | 0.0 | 0.0 | 0 |
| Isolation/Quarantine of suspected cases | 25 | 56.3 | 100 | 100 | 28.9 | 33.3 | 23.3 | |
| Contact tracing, monitoring | 25 | 50.0 | 0 | 100 | 18.4 | 16.7 | 27.1 | 0 |
| Quick reporting/recognition of cases | 25 | 59.4 | 0 | 100 | 7.9 | 4.0 | 2.3 | |
| Class II/BSL4 biosafety handling of samples | 75 | 34.4 | 100 | 100 | 5.3 | 0.3 | 3.0 | |
| Environmental decontamination | 50 | 43.8 | 100 | 100 | 18.4 | 6.7 | 13.5 | 11.5 |
| Behavior change comm/Community engagement | 25 | 18.8 | 100 | 100 | 5.3 | 4.3 | 6.8 | |
| | ||||||||
| Training donning and doffing | 0 | 40.6 | 100 | 100 | 7.9 | 6.0 | 1.5 | 3.8 |
| Observed donning and doffing | 0 | 31.3 | 0 | 100 | 2.6 | 3.3 | 0.8 | 0 |
| No exposed skin | 0 | 25.0 | 0 | 100 | 7.9 | 2.7 | 0.8 | 0 |
| Impermeable gown | 50 | 46.9 | 100 | 100 | 7.9 | 4.7 | 3.8 | 0 |
| Surgical mask | 50 | 31.3 | 100 | 100 | 7.9 | 4.0 | 3.8 | 0 |
| Face shield | 50 | 43.8 | 100 | 100 | 7.9 | 4.0 | 1.5 | 0 |
| Two sets of gloves | 50 | 46.9 | 0 | 100 | 5.3 | 5.3 | 5.3 | 0 |
| N95 mask or PAPR | 0 | 34.4 | 0 | 100 | 0.0 | 0.3 | 0.0 | 0 |
| Boots or shoe covers | 0 | 40.6 | 0 | 100 | 5.3 | 1.7 | 0.0 | 0 |
| Waterproof apron/coverall | 0 | 31.3 | 0 | 100 | 2.6 | 1.0 | 0.0 | 0 |
| | ||||||||
| Volume repletion | 25 | 65.6 | 100 | 100 | 15.8 | 6.0 | 3.8 | 0 |
| Acid base balance | 0 | 46.9 | 100 | 100 | 10.5 | 0.3 | 0.0 | 0 |
| Vasopressers | 0 | 25.0 | 0 | 0 | 5.3 | 0.7 | 0.8 | 0 |
| Oxygen | 0 | 12.5 | 100 | 100 | 2.6 | 2.0 | 1.5 | 0 |
| Pain control | 0 | 28.1 | 100 | 100 | 0.0 | 0.3 | 1.5 | 0 |
| Nutrition | 0 | 12.5 | 0 | 0 | 0.0 | 0.0 | 0.0 | 0 |
| Experimental therapies | 100 | 84.4 | 100 | 0 | 18.4 | 16.7 | 20.3 | 0 |
| Supportive treatment only | 75 | 84.4 | 100 | 100 | 13.2 | 8.7 | 2.3 | 0 |
| | ||||||||
| Travel bans (not helpful) | 0 | 0.0 | 0 | 100 | 5.3 | 4.7 | 3.0 | 3.8 |
| Screening Travelers | 0 | 56.3 | 0 | 100 | 13.2 | 14.0 | 4.5 | 15.4 |
| | ||||||||
| Liberia | 93.8 | 100 | 57.9 | 57.0 | 69.9 | 42.3 | ||
| Sierra Leone | 93.8 | 100 | 36.8 | 42.7 | 69.2 | 19.2 | ||
| Guinea | 93.8 | 100 | 28.9 | 40.7 | 68.4 | 15.4 | ||
| Nigeria | 78.1 | 0 | 23.7 | 9.0 | 6.8 | 3.8 | ||
| Senegal | 65.6 | 0 | 15.8 | 2.7 | 4.5 | 3.8 | ||
| Mali | 21.9 | 0 | 2.6 | 1.7 | 3.0 | 0 | ||
| United States | 65.6 | 100 | 57.9 | 38.3 | 27.8 | 76.9 | ||
| United Kingdom | 6.3 | 100 | 5.3 | 1.0 | 7.5 | 0 | ||
| Italy/Germany | 3.1 | 0 | 0.0 | 1.0 | 0.8 | 0 | ||
| Spain | 46.9 | 100 | 15.8 | 7.0 | 8.3 | 0 | ||
| | ||||||||
| WHO/UN | 0 | 84.4 | 100 | 100 | 21.1 | 44.0 | 59.4 | 19.2 |
| CDC | 25 | 53.1 | 100 | 100 | 42.1 | 41.3 | 30.1 | 38.5 |
| MSF | 25 | 21.9 | 100 | 100 | 18.4 | 15.0 | 20.3 | 0 |
| NIH | 0 | 18.8 | 0 | 0 | 5.3 | 12.0 | 8.3 | 7.7 |
| Dept of Transportation | 0 | 3.1 | 0 | 0 | 2.6 | 0.3 | 0.0 | 0 |
| Local Ministries of Health/Dept of health | 0 | 9.4 | 100 | 0 | 5.3 | 13.0 | 17.3 | |
| FDA | 25 | 34.4 | 100 | 100 | 2.6 | 7.0 | 7.5 | 7.7 |
| Dept of Defense/USAMRIID | 0 | 6.3 | 100 | 100 | 13.2 | 13.3 | 7.5 | 26.9 |
| USAID | 0 | 3.1 | 0 | 0 | 5.3 | 3.7 | 2.3 | 0 |
| EPA/OSHA—PPE | 0 | 12.5 | 0 | 0 | 0.0 | 0.3 | 0.0 | 0 |
| Red Cross | 0 | 3.1 | 0 | 0 | 7.9 | 3.0 | 4.5 | 0 |
| HHS/ASPR/BRADA/USPHS | 0 | 6.3 | 0 | 0 | 2.6 | 5.7 | 0.8 | 3.8 |
| | 75 | 68.8 | 100 | 100 | 2.6 | 0.3 | 3.0 | 0 |
| | 100 | 90.6 | 100 | 100 | 5.3 | 0.0 | 0.8 | 3.8 |
| | 50 | 81.3 | 100 | 100 | 7.9 | 3.0 | 6.8 | 0 |
| Historical Perspective | 100 | 68.8 | 100 | 100 | 7.9 | 1.0 | 3.0 | 3.8 |
| | 0 | 9.4 | 100 | 0 | 0.0 | 3.3 | 1.5 | 61.5 |
| | 0 | 3.1 | 0 | 0 | 0.0 | 1.0 | 0.8 | 0 |
| | 0 | 34.4 | 0 | 0 | 5.3 | 3.7 | 1.5 | 0 |
| | 0 | 3.1 | 0 | 0 | 0.0 | 0.0 | 0.0 | 19.2 |
| Medical Legal (hospital) | 0 | 0.0 | 0 | 0 | 2.6 | 4.7 | 4.5 | 11.5 |
| Medical Legal (Individual) | 0 | 0.0 | 0 | 0 | 5.3 | 2.7 | 0.0 | 7.7 |
| Celebrity donations | 0 | 0.0 | 0 | 0 | 13.2 | 0.3 | 1.5 | 0 |
| Stigma | 0 | 0.0 | 0 | 0 | 26.3 | 8.7 | 12.8 | 0 |
| Geopolitics/Response/Geofinancing | 0 | 0.0 | 0 | 0 | 5.3 | 29.0 | 21.1 | 42.3 |
| Dem Republic of Congo | 0 | 0.0 | 0 | 0 | 0.0 | 1.7 | 1.5 | 0 |
Fig 2Completeness and errors did not correlate to markers of journal quality.
Each academic press article is graphed for completeness versus impact factor (A), errors versus impact factor (B), completeness versus authors (C) and citations (D). (E) Completeness for full open access journals versus limited access is shown, red dots indicate articles that were free of errors. Errors versus authors (F), citations (G), and pages (H) are shown. (I) completeness versus page length is shown.
Fig 3Both completeness and errors were larger in academic journals.
Completeness (A) and errors (B) for each of the categories of written press. Each dot represents one article. Significance determined by ANOVA, ****—p = <0.0001, ***—p = <0.001, **—p = <0.01, *—p = <0.05, f = p value significant if outlier statistically removed from academic errors group.